SBTX Stock Overview
A life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
SkinBioTherapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.16 |
| 52 Week High | UK£0.20 |
| 52 Week Low | UK£0.07 |
| Beta | 1.77 |
| 1 Month Change | -7.78% |
| 3 Month Change | 26.98% |
| 1 Year Change | 4.06% |
| 3 Year Change | -56.04% |
| 5 Year Change | 28.00% |
| Change since IPO | 20.75% |
Recent News & Updates
Recent updates
Here's Why We're Watching SkinBioTherapeutics' (LON:SBTX) Cash Burn Situation
Mar 28
Will SkinBioTherapeutics (LON:SBTX) Spend Its Cash Wisely?
Sep 30Is SkinBioTherapeutics (LON:SBTX) In A Good Position To Deliver On Growth Plans?
Jun 11We Think SkinBioTherapeutics (LON:SBTX) Can Afford To Drive Business Growth
Feb 16We're Not Worried About SkinBioTherapeutics' (LON:SBTX) Cash Burn
Sep 29Companies Like SkinBioTherapeutics (LON:SBTX) Can Afford To Invest In Growth
Mar 23How Much Are SkinBioTherapeutics Plc (LON:SBTX) Insiders Taking Off The Table?
Jan 29Companies Like SkinBioTherapeutics (LON:SBTX) Are In A Position To Invest In Growth
Dec 07
Shareholder Returns
| SBTX | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -8.6% | -3.5% | 0.3% |
| 1Y | 4.1% | -23.5% | 6.6% |
Return vs Industry: SBTX exceeded the UK Biotechs industry which returned -23.5% over the past year.
Return vs Market: SBTX underperformed the UK Market which returned 6.6% over the past year.
Price Volatility
| SBTX volatility | |
|---|---|
| SBTX Average Weekly Movement | 11.6% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.7% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: SBTX's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: SBTX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 15 | Stuart Ashman | www.skinbiotherapeutics.com |
SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the symptoms associate with psoriasis; and MediBiotix, CleanBiotix, and PharmaBiotix which are in early stages of development. The company has an agreement with Croda Plc for the development of SkinBiotix as an active ingredient for the skicare/cosmetic industry.
SkinBioTherapeutics plc Fundamentals Summary
| SBTX fundamental statistics | |
|---|---|
| Market cap | UK£36.55m |
| Earnings (TTM) | -UK£2.88m |
| Revenue (TTM) | UK£1.21m |
30.2x
P/S Ratio-12.7x
P/E RatioIs SBTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SBTX income statement (TTM) | |
|---|---|
| Revenue | UK£1.21m |
| Cost of Revenue | UK£525.63k |
| Gross Profit | UK£683.04k |
| Other Expenses | UK£3.56m |
| Earnings | -UK£2.88m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.013 |
| Gross Margin | 56.51% |
| Net Profit Margin | -237.95% |
| Debt/Equity Ratio | 24.9% |
How did SBTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 03:35 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
SkinBioTherapeutics plc is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Christopher Donnellan | Cavendish |
| Christopher Donnellan | Cavendish Historical (Cenkos Securities) |